CDC Recommendations for Nonopioid Treatments in the Management of Chronic Pain
This COCA Call is the second in a series about CDC Guideline for Prescribing Opioids for Chronic Pain. To view a list of other webinars in the series, visit the opioid call series overview webpage.
Date:Wednesday, July 27, 2016
Deborah Dowell, MD, MPH
Senior Medical Advisor
Division of Unintentional Injury Prevention
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention
James Robinson, MD, PhD
Department of Rehabilitation Medicine
Center for Pain Relief and the Bone and Joint Surgery Center
University of Washington
David J. Tauben, MD, FACP
Chief, Division of Pain Medicine
Hughes M & Katherine G Blake Endowed Professor
Departments of Medicine and Anesthesia & Pain Medicine
University of Washington
Between 1999-2014, nonopioid treatments for chronic pain were used less frequently while the amount of opioids prescribed in the United States quadrupled. Unfortunately, long-term opioid use for chronic pain is associated with serious risks, including abuse, dependence, and overdose. In addition, there is insufficient evidence to determine whether pain relief, function, or quality of life improves with long-term opioid therapy. The CDC Guideline for Prescribing Opioids for Chronic Pain provides recommendations for safer and more effective prescribing of opioids for chronic pain in patients 18 years of age and older in outpatient settings outside of active cancer treatment, palliative care, and end-of-life care. During this COCA Call, a case study will be used to illustrate how clinicians can identify appropriate treatment strategies for chronic pain. In addition, clinicians will learn about the effectiveness and risks of nonopioid medications and nonpharmacologic treatments for chronic pain.
- State the evidence related to effectiveness and potential risks associated with nonopioid treatments for chronic pain.
- Outline nonpharmacologic and nonopioid pharmacologic treatment options for various chronic pain conditions.
- Review patient evaluation methods that can be used to identify the most appropriate treatment options for chronic pain.
- Describe the role of patient beliefs and expectations, and value of exercise, education, and nonopioid drug treatments in the management of musculoskeletal pain complaints.
- Slides: Read Nowpdf icon
- Transcript: Read Now
- Audio: Listen Nowmedia icon
- Webcast: Watch Nowmedia icon
CDC Guideline for Prescribing Opioids for Chronic Pain and Related Materials
- MMWR: CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
- JAMA Special Communication: CDC Guideline for Prescribing Opioids for Chronic Painexternal icon
Guideline Resources: Clinical Tools
- Guideline for Prescribing Opioids for Chronic Pain: Recommendationspdf icon
- Checklist for Prescribing Opioids for Chronic Painpdf icon
- Nonopioid Treatments for Chronic Painpdf icon
- Assessing Benefits and Harms of Opioid Therapypdf icon
- Calculating Total Daily Dose of Opioids for Safer Dosagepdf icon
- Prescription Drug Monitoring Programs (PDMPs)pdf icon
CDC Vital Signs
CDC Injury Prevention and Control
- CDC Prescription Drug Overdose
- Prescription Drug Overdose: What Health Care Providers Need to Know about the Epidemic
- Prescription Drug Overdose Prevention for States
Other Agency Resources
- The White House – Office of National Drug Control Policy: Opioid Abuse in the United Statespdf icon[471KB]external icon
- NIH Pain Consortium Centers of Excellence in Pain Education (CoEPEs)external icon
- Providers’ Clinical Support System for Medication Assisted Treatmentexternal icon
- Providers’ Clinical Support System for Opioid Therapiesexternal icon
- CMS Improvements to Medicare Drug and Health Plansexternal icon
- SAMHSA – Substance Abuse and Mental Health Services Administrationexternal icon
- National Institute on Drug Abuseexternal icon
- PDMP Center of Excellence, Brandeis Universityexternal icon
- Audio conference call on 7/27/16: 2:00 – 3:00 PM EST
- Web-on-demand training after 3:00 PM EST on 7/27/16
- Materials: PowerPoint slide set
“WC2286” for attendees who participate in the live call (must be completed by August 26, 2016)
“WD2286” for attendees who participate in the online presentation (must be completed by August 26, 2018)
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communications Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.
- Fees:COCA continuing education credits are free.
CME:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE:The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
IACET CEU:The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU’s for this program.
CECH:Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-149-L04-P and enduring 0387-0000-16-149-H04-P course category.
Course Category: This activity has been designated as knowledge-based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at firstname.lastname@example.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
CDC is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Effective October 1, 2013, the National Board of Public Health Examiners (NBPHE) accepts continuing education units (CEU) for CPH recertification credits from CDC. Please select CEU as your choice for continuing education when registering for a course on TCEOnline. Learners seeking CPH should use the guidelines provided by the NBPHE for calculating recertification credits. For assistance please contact NBPHE at http://www.NBPHE.orgexternal icon.
There is no cost for this program.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC does not accept commercial support.